A study testing whether a new weekly shot from Lilly, tirzepatide, can calm psoriasis.

Who can join

Adults 18+, have psoriasis, BMI 27+.

What you take

tirzepatide, given as part of the study at no cost to you. Some participants may receive a placebo (an inactive version) instead, decided at random.

How long it lasts

The full study runs about 3.2 years; your own time in it is usually shorter.

What you get

The study medication and study-related care at no cost. Compensation varies by study site; many cover travel and provide the study medication at no cost. The trial coordinator will explain what that site offers before you join.

What this study is for

Full study title: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Mode.

Primary condition: Psoriasis. Also studied in: Overweight or Obesity.

Who can join, in detail

Key inclusion criteria

• Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant)
• Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to <30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases).
• Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide.
• Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening).

Key exclusion criteria

• Have currently received ixekizumab for more than 4 months or less than 2 months.
• Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide.
• Are currently enrolled in any other clinical study.
• Have a known hypersensitivity to tirzepatide or to any of its component.
• Have a personal or family history of medullary thyroid cancer.

Where this study is enrolling

This trial has 40 US sites across 22 states. Contact the site coordinator directly to start the screening process.

Timeline

Started enrolling: 2025-03-19. Expected completion: 2028-05. Last updated on ClinicalTrials.gov: 2026-05-14.

Official source

We sync this data quarterly from ClinicalTrials.gov, the federal registry for clinical research. Before contacting a site, verify the trial is still recruiting on the official page:

View on ClinicalTrials.gov →

Other GLP-1 clinical trials

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and editorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas. About this site · LinkedIn · Contact